Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

Chronic kidney disease (CKD) represent a global health concern, and its prevalence is increasing. The ultimate therapeutic option for CKD is kidney transplantation. However, the use of drugs that target specific pathways to delay or halt CKD progression such as ACEis, ARBs and SGLT-2 inhibitors is limited in the clinical practice. Mineralocorticoid receptor (MR) activation in non-classical tissues, such as the endothelium, smooth muscle cells, inflammatory cells, podocytes, and fibroblasts may have deleterious effects on kidney structure and function.

Source: Kidney International - March 11, 2019 Category: Urology & Nephrology Authors: Jonatan Barrera-Chimal, Sophie Girerd, Frederic Jaisser Tags: Review Source Type: research